Putz
let' s not compare apples with oranges
It took me 5 minutes to find this and you will understand why they dropped to 17 cents.
Humanigen, Inc. has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases’ (NIAID) ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.
The trial did not achieve statistical significance on the primary endpoint, which was defined as the proportion of patients with baseline CRP<150 mg l and age less than 85 years, alive and without mechanical ventilation through day 29. the data also showed a non-significant trend toward a reduction in mortality in the overall patient population [hr 0.72]. there were no new safety signals attributed to lenzilumab in the activ-5 bet-b study.></150>
News 
Market Data 
Discover 
AI
